Epstein-Barr Virus in Burkitt Lymphoma in Africa Reveals a Limited Set of Whole Genome and
Burkitt lymphoma
EBV variants
East Africa
Epstein-Barr virus
LMP-1 patterns
childhood cancer
epidemiology
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
11
2021
accepted:
19
01
2022
entrez:
28
3
2022
pubmed:
29
3
2022
medline:
29
3
2022
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) is associated with endemic Burkitt lymphoma (eBL), but the contribution of EBV variants is ill-defined. Studies of EBV whole genome sequences (WGS) have identified phylogroups that appear to be distinct for Asian versus non-Asian EBV, but samples from BL or Africa, where EBV was first discovered, are under-represented. We conducted a phylogenetic analysis of EBV WGS and Epstein-Barr virus (EBV) infection, a ubiquitous infection, contributes to the etiology of both Burkitt Lymphoma (BL) and nasopharyngeal carcinoma, yet their global distributions vary geographically with no overlap. Genomic variation in EBV is suspected to play a role in the geographical patterns of these EBV-associated cancers, but relatively few EBV samples from BL have been comprehensively studied. We sought to compare phylogenetic patterns of EBV genomes obtained from BL samples in Africa and from tumor and non-tumor samples from elsewhere. We concluded that EBV obtained from BL in Africa is genetically separate from EBV in Asia. Through comprehensive analysis of nucleotide variations in EBV's
Identifiants
pubmed: 35340265
doi: 10.3389/fonc.2022.812224
pmc: PMC8948429
doi:
Types de publication
Journal Article
Langues
eng
Pagination
812224Informations de copyright
Copyright © 2022 Liao, Liu, Chin, Li, Hung, Tsai, Otim, Legason, Ogwang, Reynolds, Kerchan, Tenge, Were, Kuremu, Wekesa, Masalu, Kawira, Ayers, Pfeiffer, Bhatia, Goedert, Lo and Mbulaiteye.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EBioMedicine. 2017 Nov;25:58-65
pubmed: 29033373
Int J Cancer. 2002 May 1;99(1):93-9
pubmed: 11948498
Trends Microbiol. 2011 Jan;19(1):24-32
pubmed: 21055948
Science. 1999 Oct 8;286(5438):300-3
pubmed: 10514374
Genetics. 2000 Oct;156(2):879-91
pubmed: 11014833
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918470
Cancer Res. 2010 Apr 15;70(8):3159-69
pubmed: 20354192
Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101
pubmed: 5242134
Science. 2014 Mar 21;343(6177):1243727
pubmed: 24653038
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11030-5
pubmed: 15258291
J Infect Dis. 2012 Mar 15;205(6):906-13
pubmed: 22301635
Semin Cancer Biol. 2001 Dec;11(6):435-44
pubmed: 11669605
Virology. 1999 Aug 15;261(1):79-95
pubmed: 10441557
J Infect Dis. 2006 Feb 1;193(3):422-6
pubmed: 16388490
Virus Genes. 2007 Jan;34(1):55-61
pubmed: 16917741
J Gen Virol. 1994 Oct;75 ( Pt 10):2729-40
pubmed: 7931159
Leuk Lymphoma. 2000 Apr;37(3-4):425-9
pubmed: 10752994
IARC Sci Publ. 1975;(11 Pt 2):3-16
pubmed: 191375
J Virol. 2015 May;89(10):5222-37
pubmed: 25787276
Trends Immunol. 2014 Apr;35(4):159-69
pubmed: 24589417
Bioinformatics. 2018 Jul 15;34(14):2490-2492
pubmed: 29506019
Lancet. 1964 Mar 28;1(7335):702-3
pubmed: 14107961
Viruses. 2021 Jun 18;13(6):
pubmed: 34207433
Trop Med Int Health. 2004 Oct;9(10):1050-65
pubmed: 15482397
Mol Pathol. 2000 Oct;53(5):280-8
pubmed: 11091852
Genome Biol Evol. 2016 Dec 14;8(11):3284-3291
pubmed: 27635051
Virology. 2021 Jan 15;553:62-69
pubmed: 33238224
Sci Rep. 2019 Jul 8;9(1):9829
pubmed: 31285478
Virology. 2006 Jun 20;350(1):164-70
pubmed: 16490228
Virus Res. 2009 Aug;143(2):209-21
pubmed: 19596032
Int J Cancer. 2020 Feb 15;146(4):953-969
pubmed: 31054214
Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180299
pubmed: 30955492
J Gen Virol. 1991 Oct;72 ( Pt 10):2399-409
pubmed: 1681026
J Virol. 2017 Jul 12;91(15):
pubmed: 28515295
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771613
Semin Cancer Biol. 2014 Jun;26:99-115
pubmed: 24751797
J Natl Cancer Inst. 2002 Dec 4;94(23):1757-63
pubmed: 12464647
IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492
pubmed: 9705682
Infect Genet Evol. 2013 Jun;16:355-61
pubmed: 23538336
J Virol. 2018 Oct 29;92(22):
pubmed: 30111570
Front Oncol. 2021 Dec 14;11:804083
pubmed: 34970500
Infect Agent Cancer. 2019 Aug 1;14:17
pubmed: 31388351
J Gen Virol. 2003 Jun;84(Pt 6):1443-1450
pubmed: 12771413
J Infect Dis. 1999 Apr;179(4):763-74
pubmed: 10068570
Cancers (Basel). 2018 Jun 02;10(6):
pubmed: 29865259
PLoS One. 2008 Jun 18;3(6):e2505
pubmed: 18560562
BMJ Open. 2020 Aug 30;10(8):e037505
pubmed: 32868361
Clin Infect Dis. 2006 Aug 1;43(3):276-82
pubmed: 16804839
Nat Genet. 2019 Jul;51(7):1131-1136
pubmed: 31209392
Blood. 2019 Mar 21;133(12):1313-1324
pubmed: 30617194
J Virol. 2020 Aug 17;94(17):
pubmed: 32581102
Sci Transl Med. 2011 Nov 2;3(107):107fs7
pubmed: 22049067
Nature. 1984 Jul 19-25;310(5974):207-11
pubmed: 6087149
Sci Rep. 2015 Nov 23;5:16706
pubmed: 26593963
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4
pubmed: 8415670
Immunity. 1996 Aug;5(2):173-9
pubmed: 8769480
Nature. 1978 Aug 24;274(5673):756-61
pubmed: 210392
Nat Rev Microbiol. 2016 Mar;14(3):150-62
pubmed: 26806595
Science. 2000 Apr 14;288(5464):339-44
pubmed: 10764648
Int J Hematol. 2008 Mar;87(2):110-117
pubmed: 18256789
J Virol. 2012 Apr;86(8):4380-93
pubmed: 22318153
Viruses. 2016 Feb 24;8(3):60
pubmed: 26927157